Allergan Settles Restasis Antitrust Claims for $51.2 Million
Allergan Settles Restasis Antitrust Claims for $51.2 Million
On February 25, 2020, a class of direct purchasers of brand Restasis (cyclosporine) eye drops moved in the United States District Court for the Eastern District of New York (Gershon, J.) for an order preliminary approving a $51 million settlement reached with Allergan over allegations that Allergan deployed a multi-faceted scheme to delay generic competition to its blockbuster Restasis eye drop franchise.
The alleged scheme included Allergan’s attempt to transfer relevant Restasis patents to the Saint Regis Mohawk Tribe to invoke the Tribe’s sovereign immunity as a patent invalidation defense, a unprecedented tactic that sparked Congressional investigations as well as an amici filing from the Department of Justice. Reviewing courts ultimately rejected the tactic — what the DOJ characterized as Allergan’s “commercial rental of a tribe’s sovereign immunity” — and the United States Supreme Court denied certiorari.
Faruqi and Faruqi, LLP is one of leading firms representing the direct purchaser class plaintiffs.
Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in Atlanta, Los Angeles and Philadelphia.
Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, direct purchasers, consumers and employees.
To schedule a free consultation with our attorneys and to learn more about your legal rights, call our offices today at (877) 247-4292 or (212) 983-9330.
Bradley J. Demuth’s practice is focused on complex antitrust litigation with particular expertise in cases involving pharmaceutical overcharges resulting from delayed generic entry schemes, price fixing, and other anticompetitive conduct. Brad is a partner in the firm’s New York office.
